Melatonin's role as a co-adjuvant treatment in colonic diseases: A review

Life Sciences

Volumn 170, Issue , 2017, Pages 72-81

  Esteban Zubero, Eduardo ^a   López Pingarrón, Laura ^a   Alatorre Jiménez, Moisés Alejandro ^b   Ochoa Moneo, Purificación ^a   Buisac Ramón, Celia ^c   Rivas Jiménez, Miguel ^a   Castán Ruiz, Silvia ^c   Antoñanzas Lombarte, Ángel ^a   Tan, Dun Xian ^b   García, José Joaquín ^a   Reiter, Russel J ^b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c Primary Care Administration   (Spain)

Author keywords

Crohn's disease; Gastrointestinal diseases; Irritable bowel syndrome; Melatonin; Necrotizing enterocolitis; Ulcerative colitis

Indexed keywords

MELATONIN; MELATONIN RECEPTOR; SEROTONIN;

ADJUVANT THERAPY; COLON DISEASE; CROHN DISEASE; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; HUMAN; INFLAMMATORY BOWEL DISEASE; NECROTIZING ENTEROCOLITIS; REVIEW; SLEEP QUALITY; ULCERATIVE COLITIS; ANIMAL; CELL PROLIFERATION; COLITIS; CYTOLOGY; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; INTESTINE; IRRITABLE COLON; METABOLISM; PHYSIOLOGY; PINEAL BODY; RISK FACTOR; SECRETION (PROCESS); SLEEP; TH17 CELL; TH2 CELL;

ANIMALS; CELL PROLIFERATION; COLITIS; COLITIS, ULCERATIVE; COLONIC DISEASES; ENTEROCOLITIS, NECROTIZING; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MELATONIN; PINEAL GLAND; RECEPTORS, MELATONIN; RISK FACTORS; SEROTONIN; SLEEP; TH17 CELLS; TH2 CELLS;

EID: 85008957112     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.11.031     Document Type: Review

References (203)

1. [1] Chen, C.Q., Fichna, J., Bashashati, M., Li, Y.Y., Storr, M., Distribution, function and physiological role of melatonin in the lower gut. World J. Gastroenterol. 17 (2011), 3888–3898.
2. [2] Soták, M., Mrnka, L., Pácha, J., Heterogeneous expression of melatonin receptor MT1 mRNA in the rat intestine under control and fasting conditions. J. Pineal Res. 41 (2006), 183–188.
3. [3] Bubenik, G.A., Gastrointestinal melatonin: localization, function, and clinical relevance. Dig. Dis. Sci. 47 (2002), 2336–2348.
4. [4] Drago, F., Macauda, S., Salehi, S., Small doses of melatonin increase intestinal motility in rats. Dig. Dis. Sci. 47 (2002), 1969–1974.
5. [5] Kasimay, O., Cakir, B., Devseren, E., Yegen, B.C., Exogenous melatonin delays gastric emptying rate in rats: role of CCK2 and 5-HT3 receptors. J. Physiol. Pharmacol. 56 (2005), 543–553.
6. [6] Manocha, M., Khan, W.I., Serotonin and GI disorders: an update on clinical and experimental studies. Clin. Transl. Gastroenterol., 26(3), 2012, e13, 10.1038/ctg.2012.8.
7. [7] Konturek, P.C., Brzozowski, T., Konturek, S.J., Gut clock: implications for circadian rhythms in the gastrointestinal tract. J. Physiol. Pharmacol. 62 (2011), 139–150.
8. [8] Reiter, R.J., Tan, D.X., Mayo, J.C., Leon, J., Bandyopadhyay, D., Neurally-mediated and neurally-independent beneficial actions of melatonin in the gastrointestinal tract. J. Physiol. Pharmacol. 54:Suppl. 4 (2003), 113–125.
9. [9] Mozaffari, S., Nikfar, S., Abdollahi, M., Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opin. Drug Metab. Toxicol. 9 (2013), 403–421.
10. [10] Matheus, N., Mendoza, C., Iceta, R., Mesonero, J.E., Alcalde, A.I., Melatonin inhibits serotonin transporter activity in intestinal epithelial cells. J. Pineal Res. 48 (2010), 332–339.
11. [11] Martín, T.M., Azpiroz, F., Malagelada, J.R., Melatonin as a modulator of the ileal brake mechanism. Scand. J. Gastroenterol. 40 (2005), 559–563.
12. [12] Barajas-Lopez, C., Peres, A.L., Espinosa-Luna, R., Reyes-Vázquez, C., Prieto-Gómez, B., Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucous plexus. Eur. J. Pharmacol. 312 (1996), 319–325.
13. [13] Storr, M., Koppitz, P., Sibaev, A., Saur, D., Kurjak, M., Franck, H., Schusdziarra, V., Allescher, H.D., Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. J. Pineal Res. 33 (2002), 101–108.
14. [14] Velarde, E., Alonso-Gómez, A.L., Azpeleta, C., Isorna, E., Delgado, M.J., Melatonin attenuates the acetylcholine-induced contraction in isolated intestine of a teleost fish. J. Comp. Physiol. B. 179 (2009), 951–959.
15. [15] De Filippis, D., Iuvone, T., Esposito, G., Steardo, L., Arnold, G.H., Paul, A.P., De Man Joris, G., De Winter Benedicte, Y., Melatonin reverses lipopolysaccharide-induced gastro-intestinal motility disturbances through the inhibition of oxidative stress. J. Pineal Res. 44 (2008), 45–51.
16. [16] Merle, A., Delagrange, P., Renard, P., Lesieur, D., Cuber, J.C., Roche, M., Pellissier, S., Effect of melatonin on motility pattern of small intestine in rats and its inhibition by melatonin receptor antagonist S 22153. J. Pineal Res. 29 (2000), 116–124.
17. [17] Mickle, A., Sood, M., Zhang, Z., Shahmohammadi, G., Sengupta, J.N., Miranda, A., Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: a centrally mediated process. Pain 149 (2010), 555–564.
18. [18] Carrillo-Vico, A., Reiter, R.J., Lardone, P.J., Herrera, J.L., Fernández-Montesinos, R., Guerrero, J.M., Pozo, D., The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs 7 (2006), 423–431.
19. [19] Mei, Q., Yu, J.P., Xu, J.M., Wei, W., Xiang, L., Yue, L., Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol. Sin. 23 (2002), 882–886.
20. [20] Mrnka, L., Hock, M., Rybová, M., Pácha, J., Melatonin inhibits prostaglandin E2- and sodium nitroprusside-induced ion secretion in rat distal colon. Eur. J. Pharmacol. 581 (2008), 164–170.
21. [21] Mozaffari, S., Rahimi, R., Abdollahi, M., Implications of melatonin therapy in irritable bowel syndrome: a systematic review. Curr. Pharm. Des. 16 (2010), 3646–3655.
22. [22] Bandyopadhyay, D., Biswas, K., Bandyopadhyay, U., Reiter, R.J., Banerjee, R.K., Melatonin protects against stress-induced gastric lesions by scavenging the hydroxyl radical. J. Pineal Res. 29 (2000), 143–151.
23. [23] Klupińska, G., Poplawski, T., Drzewoski, J., Harasiuk, A., Reiter, R.J., Blasiak, J., Chojnacki, J., Therapeutic effect of melatonin in patients with functional dyspepsia. J. Clin. Gastroenterol. 41 (2007), 270–274.
24. [24] Brzozowski, T., Konturek, P.C., Zwirska-Korczala, K., Konturek, S.J., Brzozowska, I., Drozdowicz, D., Sliwowski, Z., Pawlik, M., Pawlik, W.W., Hahn, E.G., Importance of the pineal gland, endogenous prostaglandins and sensory nerves in the gastroprotective actions of central and peripheral melatonin against stress-induced damage. J. Pineal Res. 39 (2005), 375–385.
25. [25] Reiter, R.J., Tan, D.X., Jou, M.J., Korkmaz, A., Manchester, L.C., Paredes, S.D., Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro Endocrinol. Lett. 29 (2008), 391–398.
26. 2 is protected by the antioxidants melatonin, N1-acetyl-N2-formyl-5-methyoxykynuramine, resveratrol and uric acid. Int. J. Biochem. Cell Biol. 33 (2001), 775–783.
27. [27] Reiter, R.J., Tan, D.X., Maldonado, M.D., Melatonin as an antioxidant: physiology versus pharmacology. J. Pineal Res. 39 (2005), 215–216.
28. [28] Manchester, L.C., Coto-Montes, A., Boga, J.A., Andersen, L.P., Zhou, Z., Galano, A., Vriend, J., Tan, D.X., Reiter, R.J., Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J. Pineal Res. 59 (2015), 403–419.
29. [29] Reiter, R.J., Mayo, J.C., Tan, D.X., Sainz, R.M., Alatorre-Jimenez, M., Qin, L., Melatonin as an antioxidant: under promises but over delivers. J. Pineal Res. 61 (2016), 253–278.
30. [30] Finkel, T., Holbrook, N.J., Oxidants, oxidative stress and the biology of ageing. Nature 408 (2000), 239–247.
31. [31] Galano, A., Tan, D.X., Reiter, R.J., Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 51 (2011), 1–16.
32. [32] Reiter, R.J., Tan, D.X., Galano, A., Melatonin: exceeding expectations. Physiology (Bethesda) 29 (2014), 325–333.
33. [33] Patel, R.P., McAndrew, J., Sellak, H., White, C.R., Jo, H., Freeman, B.A., Darley-Usmar, V.M., Biological aspects of reactive nitrogen species. Biochim. Biophys. Acta 1411 (1999), 385–400.
34. [34] Barlow-Walden, L.R., Reiter, R.J., Abe, M., Pablos, M., Menendez-Pelaez, A., Chen, L.D., Poeggeler, B., Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int. 26 (1995), 497–502.
35. [35] Okatani, Y., Wakatsuki, A., Shinohara, K., Kaneda, C., Fukaya, T., Melatonin stimulates glutathione peroxidase activity in human chorion. J. Pineal Res. 30 (2001), 199–205.
36. [36] Pablos, M.I., Reiter, R.J., Ortiz, G.G., Guerrero, J.M., Agapito, M.T., Chuang, J.I., Sewerynek, E., Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem. Int. 32 (1998), 69–75.
37. [37] Reiter, R.J., Tan, D.X., Osuna, C., Gitto, E., Actions of melatonin in the reduction of oxidative stress: a review. J. Biomed. Sci. 7 (2000), 444–458.
38. [38] Rodriguez, C., Mayo, J.C., Sainz, R.M., Antolín, I., Herrera, F., Martín, V., Reiter, R.J., Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 36 (2004), 1–9.
39. [39] Pozo, D., Reiter, R.J., Calvo, J.R., Guerrero, J.M., Inhibition of cerebellar nitric oxide synthase and cyclic AMP production via complex formation with calmodulin. J. Cell. Biochem. 65 (1997), 430–442.
40. [40] Urata, Y., Honma, S., Goto, S., Todoroki, S., Iida, T., Cho, S., Honma, K., Kondo, T., Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein 1 in human vascular endothelial cells. Free Radic. Biol. Med. 27 (1999), 838–847.
41. [41] Gitto, E., Tan, D.X., Reiter, R.J., Karbownik, M., Manchester, L.C., Cuzzocrea, S., Fulia, F., Barberi, I., Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J. Pharm. Pharmacol. 53 (2001), 1393–1401.
42. [42] Valko, M., Morris, H., Cronin, M.T., Metals, toxicity and oxidative stress. Curr. Med. Chem. 12 (2005), 1161–1208.
43. [43] Galano, A., Medina, M.E., Tan, D.X., Reiter, R.J., Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physiochemical analysis. J. Pineal Res. 58 (2015), 107–116.
44. [44] Hungin, A.P., Whorwell, P.J., Tack, T., Mearin, F., The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther. 17 (2003), 643–650.
45. [45] Okatani, Y., Marioka, N., Wakatsuki, A., Changes in nocturnal melatonin secretion in perimenopausal women: correlation with endogenous estrogen concentrations. J. Pineal Res. 20 (2000), 111–118.
46. [46] Walecka-Kapica, E., Chojnacki, J., Stępień, A., Wachowska-Kelly, P., Klupińska, G., Chojnacki, C., Melatonin and female hormone secretion in postmenopausal overweight women. Int. J. Mol. Sci. 16 (2015), 1030–1142.
47. [47] Malinen, E., Rinttilä, T., Kajander, K., Mättö, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., Palva, A., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am. J. Gastroenterol. 100 (2005), 373–382.
48. [48] Konturek, S.J., Konturek, P.C., Brzozowska, I., Pawlik, M., Sliwowski, Z., Cześnikiewicz-Guzik, M., Kwiecień, S., Brzozowski, T., Bubenik, G.A., Pawlik, W.W., Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J. Physiol. Pharmacol. 58 (2007), 381–405.
49. [49] Martinez, V., Tache, Y., Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res. 893 (2001), 29–35.
50. [50] Tache, Y., Martinez, V., Million, M., Wang, L., Stress and the gastrointestinal tract. III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 280 (2001), G173–G177.
51. [51] Tache, Y., Perdue, M.H., Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol. Motil. 16:Suppl. 1 (2004), 137–142.
52. [52] Fass, R., Fullerton, S., Tung, S., Mayer, E.A., Sleep disturbances in clinic patients with functional bowel disorders. Am. J. Gastroenterol. 95 (2000), 1195–2000.
53. [53] Thompson, J.J., Elsenbruch, S., Harnish, M.J., Orr, W.C., Autonomic functioning during REM sleep differentiates IBS symptom subgroups. Am. J. Gastroenterol. 97 (2002), 3147–3153.
54. [54] Jarrett, M., Heitkemper, M., Cain, K.C., Burr, R.L., Hertig, V., Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome. Dig. Dis. Sci. 45 (2000), 952–959.
55. [55] Fitzgerald, P., Cassidy Eugene, M., Scully, P., Barry, S., Quigley Eamonn, M.M., Shanahan, F., Cryan, J., Dinan Timothy, G., Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol. Motil. 20 (2008), 1291–1297.
56. [56] Clarke, G., Fitzgerald, P., Cryan, J.F., Cassidy, E.M., Quigley, E.M., Dinan, T.G., Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol., 9, 2009, 6, 10.1186/1471-230X-9-6.
57. [57] Kennedy, P.J., Allen, A.P., O'Neill, A., Quigley, E.M., Cryan, J.F., Dinan, T.G., Clarke, G., Acute tryptophan depletion reduces kynurenine levels: implications for treatment of impaired visuospatial memory performance in irritable bowel syndrome. Psychopharmacology 232 (2015), 1357–1371.
58. [58] Heitkemper, M.M., Han, C.J., Jarrett, M.E., Gu, H., Djukovic, D., Shulman, R.J., Raftery, D., Henderson, W.A., Cain, K.C., Serum tryptophan metabolite levels during sleep in patients with and without irritable bowel syndrome (IBS). Biol. Res. Nurs. 18 (2016), 193–198.
59. [59] Pääkkönen, T., Mäkinen, T.M., Leppäluoto, J., Vakkuri, O., Rintamäki, H., Palinkas, L.A., Hassi, J., Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions. J. Pineal Res. 40 (2006), 110–115.
60. [60] Wisniewska-Jarosinska, M., Chojnacki, J., Konturek, S., Konturek, S., Brzozowski, T., Smigielski, J., Chojnacki, C., Evaluation of urinary 6-hydroxymelatonin sulphate excretion in women at different age with irritable bowel syndrome. J. Physiol. Pharmacol. 61 (2010), 295–300.
61. [61] Radwan, P., Skrzydło-Romańska, B., Radwan-Kwiatek, K., Burak-Czapiuk, B., Strzemecka, J., Is melatonin involved in the irritable bowel syndrome?. J. Physiol. Pharmacol. 60:Suppl. 3 (2009), 67–70.
62. [62] Chojnack, C., Wiśniewska-Jarosińska, M., Kulig, G., Majsterek, I., Reiter, R.J., Chojnacki, J., Evaluation of enterochromaffin cells and melatonin secretion exponents in ulcerative colitis. World J. Gastroenterol. 19 (2013), 3602–3607.
63. [63] Shirakawa, S., Tsuchiya, S., Tsutsumi, Y., Time course of saliva and serum melatonin levels after ingestion of melatonin. Psychiatry Clin. Neurosci. 52 (1998), 266–267.
64. [64] Hammerle, C.W., Surawicz, C.M., Updates on treatment of irritable bowel syndrome. World J. Gastroenterol. 14 (2008), 2639–2649.
65. [65] Chey, W.D., Tegaserod and other serotonergic agents. What is the evidence?. Rev. Gastroenterol. Disord. 3 (2003), S35–S40.
66. [66] Andersen, V., Camilleri, M., Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs 66 (2006), 1073–1088.
67. [67] Storr, M., Schusdziarra, V., Allescher, H.D., Inhibition of small conductance K +-channels attenuated melatonin-induced relaxation of serotonin-contracted rat gastric fundus. Can. J. Physiol. Pharmacol. 78 (2000), 799–806.
68. [68] Song, G.H., Gwee, K.A., Moochhala, S.M., Ho, K.Y., Melatonin attenuates stress-induced defecation: lesson from a rat model of stress-induced gut dysfunction. Neurogastroenterol. Motil. 17 (2005), 744–750.
69. [69] Tan, W., Zhou, W., Luo, H.S., Liang, C.B., Xia, H., The inhibitory effect of melatonin on colonic motility disorders induced by water avoidance stress in rats. Eur. Rev. Med. Pharmacol. Sci. 17 (2013), 3060–3067.
70. [70] Han, J.H., Chang, I.H., Myung, S.C., Lee, M.Y., Kim, W.Y., Lee, S.Y., Lee, S.Y., Lee, S.W., Kim, K.D., A novel pathway underlying the inhibitory effects of melatonin on isolated rat urinary bladder contraction. Korean J. Physiol. Pharmacol. 16 (2012), 37–42.
71. [71] Semerciöz, A., Onur, R., Ayar, A., Orthan, I., The inhibitory role of melatonin on isolated guinea-pig urinary bladder: an endogenous hormone effect. BJU Int. 94 (2004), 1373–1376.
72. [72] Lu, W.Z., Song, G.H., Gwee, K.A., Ho, K.Y., The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig. Dis. Sci. 54 (2009), 1087–1093.
73. [73] Song, G.H., Leng, P.H., Gwee, K.A., Moochhala, S.M., Ho, K.Y., Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 54 (2005), 1402–1407.
74. [74] Saha, L., Malhotra, S., Rana, S., Bhasin, D., Pandhi, P., A preliminary study of melatonin in irritable bowel syndrome. J. Clin. Gastroenterol. 41 (2007), 29–32.
75. [75] Gonciarz, M., Gonciarz, Z., Bielanski, W., Mularczyk, A., Konturek, P.C., Brzozowski, T., Konturek, S.J., The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J. Physiol. Pharmacol. 63 (2012), 35–40.
76. [76] Stein, R.B., Lichtenstein, G.R., Medical therapy for Crohn's disease: the state of the art. Surg. Clin. North Am. 81 (2001), 71–101.
77. [77] Talley, N.J., Abreu, M.T., Achkar, J.P., Bernstein, C.N., Dubinsky, M.C., Hanauer, S.B., Kane, S.V., Sandborn, W.J., Ullman, T.A., Moayyedi, P., American College of Gastroenterology IBD Task Force, An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am. J. Gastroenterol. 106:Suppl. 1 (2011), S2–25 (quiz S26).
78. [78] Kaser, A., Zeissig, S., Blumberg, R.S., Inflammatory bowel disease. Annu. Rev. Immunol. 28 (2010), 573–621.
79. [79] O'Toole, A., Korzenik, J., Environmental triggers for IBD. Curr. Gastroenterol. Rep., 16, 2014, 396, 10.1007/s11894-014-0396-y.
80. [80] Parkes, G.C., Whelan, K., Lindsay, J.O., Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J. Crohns Colitis 8 (2014), 717–725.
81. [81] Ananthakrishnan, A.N., Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 205–217.
82. [82] Paulose, J.K., Wright, J.M., Patel, A.G., Cassone, V.M., Human gut bacteria are sensitive to melatonin and express endogenous circadian activity. PLoS One, 11, 2016, e0146643, 10.1371/journal.pone.0146643.
83. [83] Paulose, J.K., Cassone, V.M., The melatonin sensitive circadian clock of the enteric bacterium Enterobacter aerogenes. Gut Microbes 7 (2016), 1–4.
84. [84] Ali, T., Madhoun, M.F., Orr, W.C., Rubin, D.T., Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm. Bowel Dis. 19 (2013), 2440–2443.
85. [85] Graff, L.A., Clara, I., Walker, J.R., Lix, L., Carr, R., Miller, N., Rogala, L., Bernstein, C.N., Changes in fatigue over 2 years are associated with activity of inflammatory bowel disease and psychological factors. Clin. Gastroenterol. Hepatol. 11 (2013), 1140–1146.
86. [86] Ananthakrishnan, A.N., Long, M.D., Martin, C.F., Sandler, R.S., Kappelman, M.D., Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin. Gastroenterol. Hepatol. 11 (2013), 965–971.
87. [87] Ranjbaran, Z., Keefer, L., Farhadi, A., Stepanski, E., Sedghi, S., Keshavarzian, A., Impact of sleep disturbances in inflammatory bowel disease. J. Gastroenterol. Hepatol. 22 (2007), 1748–1753.
88. [88] Parekh, P.J., Oldfield Iv, E.C., Challapallisri, V., Ware, J.C., Johnson, D.A., Sleep disorders and inflammatory disease activity: chicken or the egg?. Am. J. Gastroenterol. 110 (2015), 484–488.
89. [89] Calvo, J.R., Guerrero, J.M., Osuna, C., Molinero, P., Carrillo-Vico, A., Melatonin triggers Crohn's disease symptoms. J. Pineal Res. 32 (2002), 277–278.
90. [90] Strober, W., Fuss, I.J., Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140 (2011), 1756–1767.
91. [91] Fuss, I.J., Neurath, I.J.M., Boirivant, M., Klein, J.S., de la Motte, C., Strong, S.A., Fiocchi, C., Strober, W., Disparate CD4 + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157 (1996), 1261–1270.
92. [92] Graham, D.B., Xavier, R.J., From genetics of inflammatory bowel disease towards mechanistic insights. Trends Immunol. 34 (2013), 371–378.
93. [93] Garcia-Mauriño, S., Gonzalez-Haba, M.G., Calvo, J.R., Rafii-El-Idrissi, M., Sanchez-Margalet, V., Goberna, R., Guerrero, J.M., Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4 + cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 159 (1997), 574–581.
94. [94] García-Mauriño, S., Pozo, D., Carrillo-Vico, A., Calvo, J.R., Guerrero, J.M., Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci. 65 (1999), 2143–2150.
95. [95] Coskun, M., Salem, M., Pedersen, J., Nielsen, O.H., Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol. Res. 76 (2013), 1–8.
96. [96] Vuitton, L., Koch, S., Peyrin-Biroulet, L., Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Curr. Drug Targets 14 (2013), 1385–1391.
97. [97] He, P., Ouyang, X., Zhou, S., Yin, W., Tang, C., Laudon, M., Tian, S., A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer’ disease. Horm. Behav. 64 (2013), 1–7.
98. [98] Buendia, I., Gómez-Rangel, V., González-Lafuente, L., Parada, E., León, R., Gameiro, I., Michalska, P., Laudon, M., Egea, J., López, M.G., Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models. Neuropharmacology 99 (2015), 187–195.
99. [99] Zhang, J.X., Song, J., Wang, J., Dong, W.G., JAK2 rs10758669 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. Inflammation 37 (2014), 793–800.
100. [100] Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J., Pflanz, S., Zhang, R., Singh, K.P., Vega, F., To, W., Wagner, J., O'Farrell, A.M., McClanahan, T., Zurawski, S., Hannum, C., Gorman, D., Rennick, D.M., Kastelein, R.A., de Waal Malefyt, R., Moore, K.W., A receptor for the heterodimeric cytokine IL-23 is composed of IL- 12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168 (2012), 5699–5708.
101. [101] Durant, L., Watford, W.T., Ramos, H.L., Laurence, A., Vahedi, G., Wei, L., Takahashi, H., Sun, H.W., Kanno, Y., Powrie, F., O'Shea, J.J., Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32 (2010), 605–615.
102. [102] Stritesky, G.L., Muthukrishnan, R., Sehra, S., Goswami, R., Pham, D., Travers, J., Nguyen, E.T., Levy, D.E., Kaplan, M.H., The transcription factor STAT3 is required for T helper 2 cell development. Immunity 34 (2011), 39–49.
103. [103] Chen, Y., Xiao, Y., Ge, W., Zhou, K., Wen, J., Yan, W., Wang, Y., Wang, B., Qu, C., Wu, J., Xu, L., Cai, W., miR-200b inhibits TGF-β1-induced epithelial-mesenchymal transition and promotes growth of intestinal epithelial cells. Cell Death Dis., 4, 2013, e541, 10.1038/cddis.2013.22.
104. [104] Monteleone, G., Pallone, F., Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med., 372, 2015, 2461, 10.1056/NEJMc1504845.
105. [105] Hara, T., Otsuka, F., Tsukamoto-Yamauchi, N., Inagaki, K., Hosoya, T., Nakamura, E., Terasaka, T., Komatsubara, M., Makino, H., Mutual effects of melatonin and activin on induction of aldosterone production by human adrenocortical cells. J. Steroid Biochem. Mol. Biol. 152 (2015), 8–15.
106. [106] Pastorelli, L., De Salvo, C., Mercado, J.R., Vecchi, M., Pizarro, T.T., Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front. Immunol., 4, 2013, 280, 10.3389/fimmu.2013.00280.
107. [107] Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., Stockinger, B., TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006), 179–189.
108. [108] Ivanov, I.I., Zhou, L., Littman, D.R., Transcriptional regulation of Th17 cell differentiation. Semin. Immunol. 19 (2007), 409–417.
109. [109] McGeachy, M.J., Chen, Y., Tato, C.M., Laurence, A., Joyce-Shaikh, B., Blumenschein, W.M., McClanahan, T.K., O'Shea, J.J., Cua, D.J., The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 10 (2009), 314–324.
110. [110] Farez, M.F., Mascanfroni, I.D., Méndez-Huergo, S.P., Yeste, A., Murugaiyan, G., Garo, L.P., Balbuena Aguirre, M.E., Patel, B., Ysrraelit, M.C., Zhu, C., Kuchroo, V.K., Rabinovich, G.A., Quintana, F.J., Correale, J., Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell 162 (2015), 1338–1352.
111. [111] Izcue, A., Hue, S., Buonocore, S., Arancibia-Cárcamo, C.V., Ahern, P.P., Iwakura, Y., Maloy, K.J., Powrie, F., Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28 (2008), 559–570.
112. [112] Ahern, P.P., Schiering, C., Buonocore, S., McGeachy, M.J., Cua, D.J., Maloy, K.J., F. Powrie interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33 (2010), 279–288.
113. [113] Kleinschek, M.A., Boniface, K., Sadekova, S., Grein, J., Murphy, E.E., Turner, S.P., Raskin, L., Desai, B., Faubion, W.A., de Waal Malefyt, R., Pierce, R.H., McClanahan, T., Kastelein, R.A., Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206 (2009), 525–534.
114. [114] Sakuraba, A., Sato, T., Kamada, N., Kitazume, M., Sugita, A., Hibi, T., Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 137 (2009), 1736–1745.
115. [115] Head, K.A., Jurenka, J.S., Inflammatory bowel disease part 1: ulcerative colitis—pathophysiology and conventional and alternative treatment options. Altern. Med. Rev. 8 (2003), 247–283.
116. [116] Jess, T., Rungoe, C., Peyrin-Biroulet, L., Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of populationbased cohort studies. Clin. Gastroenterol. Hepatol. 10 (2012), 639–645.
117. [117] Peterson, C.T., Sharma, V., Elmen, L., Peterson, S.N., Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin. Exp. Immunol. 179 (2015), 363–377.
118. [118] Holubar, S.D., Cima, R.R., Sandborn, W.J., Pardi, D.S., Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst. Rev., 6, 2010, CD001176, 10.1002/14651858.CD001176.pub2.
119. [119] Stremmel, W., Merle, U., Zahn, A., Autschbach, F., Hinz, U., Ehehalt, R., Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 54 (2005), 966–971.
120. [120] Sandborn, W.J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., Niezychowski, W., Study A3921063 Investigators, Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367 (2012), 616–624.
121. [121] Mannon, P.J., Hornung, R.L., Yang, Z., Yi, C., Groden, C., Friend, J., Yao, M., Strober, W., Fuss, I.J., Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production. Gut 60 (2011), 449–455.
122. [122] Feagan, B.G., Rutgeerts, P., Sands, B.E., Hanauer, S., Colombel, J.F., Sandborn, W.J., Van Assche, G., Axler, J., Kim, H.J., Danese, S., Fox, I., Milch, C., Sankoh, S., Wyant, T., Xu, J., Parikh, A., GEMINI 1 Study Group, Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369 (2013), 699–710.
123. [123] Vermeire, S., O'Byrne, S., Keir, M., Williams, M., Lu, T.T., Mansfield, J.C., Lamb, C.A., Feagan, B.G., Panes, J., Salas, A., Baumgart, D.C., Schreiber, S., Dotan, I., Sandborn, W.J., Tew, G.W., Luca, D., Tang, M.T., Diehl, L., Eastham-Anderson, J., De Hertogh, G., Perrier, C., Egen, J.G., Kirby, J.A., van Assche, G., Rutgeerts, P., Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384 (2014), 309–318.
124. [124] Bernardini, N., Segnani, C., Ippolito, C., De Giorgio, R., Colucci, R., Faussone-Pellegrini, M.S., Chiarugi, M., Campani, D., Castagna, M., Mattii, L., Blandizzi, C., Dolfi, A., Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J. Cell. Mol. Med. 16 (2012), 318–327.
125. [125] Jena, G., Trivedi, P.P., A review of the use of melatonin in ulcerative colitis: experimental evidence and new approaches. Inflamm. Bowel Dis. 20 (2014), 553–563.
126. [126] Sprong, T., Peri, G., Neeleman, C., Mantovani, A., Signorini, S., van der Meer, J.W., van Deuren, M., Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock 31 (2009), 28–32.
127. [127] Harder, B., Jiang, T., Wu, T., Tao, S., Rojo de la Vega, M., Tian, W., Chapman, E., Zhang, D.D., Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention. Biochem. Soc. Trans. 43 (2015), 680–686.
128. [128] Crespo, I., Miguel, B.S., Laliena, A., Alvarez, M., Culebras, J.M., González-Gallego, J., Tuñón, M.J., Melatonin prevents the decreased activity of antioxidant enzymes and activates nuclear erythroid 2-related factor 2 signaling in an animal model of fulminant hepatic failure of viral origin. J. Pineal Res. 49 (2010), 193–200.
129. [129] Zhou, L., Zhao, D., An, H., Zhang, H., Jiang, C., Yang, B., Melatonin prevents lung injury induced by hepatic ischemia-reperfusion through anti-inflammatory and anti-apoptosis effects. Int. Immunopharmacol. 29 (2015), 462–467.
130. [130] Wang, D., Wei, Y., Wang, T., Wan, X., Yang, C.S., Reiter, R.J., Zhang, J., Melatonin attenuates (−)- epigallocatehin-3-gallate-triggered hepatotoxicity without compromising its downregulation of hepatic gluconeogenic and lipogenic genes in mice. J. Pineal Res. 59 (2015), 497–507.
131. [131] Shang, B., Shi, H., Wang, X., Guo, X., Wang, N., Wang, Y., Dong, L., Protective effect of melatonin on myenteric neuron damage in experimental colitis in rats. Fundam. Clin. Pharmacol. 30 (2016), 117–127.
132. [132] Chojnacki, C., Wisniewska-Jarosinska, M., Walecka-Kapica, E., Klupinska, G., Jaworek, J., Chojnacki, J., Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J. Physiol. Pharmacol. 62 (2011), 327–334.
133. [133] Chen, M., Mei, Q., Xu, J., Lu, C., Fang, H., Liu, X., Detection of melatonin and homocysteine simultaneously in ulcerative colitis. Clin. Chim. Acta 413 (2012), 30–33.
134. [134] Chung, S.H., Park, Y.S., Kim, O.S., Kim, J.H., Baik, H.W., Hong, Y.O., Kim, S.S., Shin, J.H., Jun, J.H., Jo, Y., Ahn, S.B., Jo, Y.K., Son, B.K., Kim, S.H., Melatonin attenuates dextran sodium sulfate induced colitis with sleep deprivation: possible mechanism by microarray analysis. Dig. Dis. Sci. 59 (2014), 1134–1141.
135. [135] Cross, R.K., Wilson, K.T., Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 9 (2003), 179–189.
136. [136] Danese, S., Motte Cd Cde, L., Fiocchi, C., Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 99 (2004), 938–945.
137. [137] Fuss, I.J., Heller, F., Boirivant, M., Leon, F., Yoshida, M., Fichtner-Feigl, S., Yang, Z., Exley, M., Kitani, A., Blumberg, R.S., Mannon, P., Strober, W., Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113 (2014), 1490–1497.
138. [138] Boirivant, M., Fuss, I.J., Chu, A., Strober, W., Oxazalone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188 (1998), 1929–1939.
139. [139] Heller, F., Fuss, I.J., Nieuwenhuis, E.E., Blumberg, R.S., Strober, W., Oxazalone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17 (2002), 629–638.
140. [140] Zhou, L.L., Wei, W., Si, J.F., Yuan, D.P., Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice. Mediat. Inflamm., 2010, 10.1155/2010/951210 (pii: 951210).
141. [141] Perez-de-Arce, K., Foncea, R., Leighton, F., Reactive oxygen species mediates homocysteine-induced mitochondrial biogenesis in human endothelial cells: modulation by antioxidants. Biochem. Biophys. Res. Commun. 338 (2005), 1103–1109.
142. [142] Lazzerini, P.E., Capecchi, P.L., Selvi, E., Lorenzini, S., Bisogno, S., Galeazzi, M., Laghi Pasini, F., Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun. Rev. 6 (2007), 503–509.
143. [143] Zezos, P., Papaioannou, G., Nikolaidis, N., Patsiaoura, K., Papageorgiou, A., Vassiliadis, T., Giouleme, O., Evgenidis, N., Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. Aliment. Pharmacol. Ther. 23 (2006), 1443–1453.
144. [144] Zezos, P., Papaioannou, G., Nikolaidis, N., Vasiliadis, T., Giouleme, O., Evgenidis, N., Hyperhomocysteinemia in ulcerative colitis is related to folate level. World J. Gastroenterol. 11 (2005), 6038–6042.
145. [145] Erzin, Y., Uzun, H., Celik, A.F., Aydin, S., Dirican, A., Uzunismail, H., Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications. J. Clin. Gastroenterol. 42 (2008), 481–486.
146. [146] Heydrick, S.J., Weiss, N., Thomas, S.R., Cap, A.P., Pimentel, D.R., Loscalzo, J., Keaney, J.F. Jr., L-Homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. Free Radic. Biol. Med. 36 (2004), 632–640.
147. [147] Cuzzocrea, S., Mazzon, E., Serraino, I., Lepore, V., Terranova, M.L., Ciccolo, A., Caputi, A.P., Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J. Pineal Res. 30 (2001), 1–12.
148. [148] Dong, W.G., Mei, Q., Yu, J.P., Xu, J.M., Xiang, L., Xu, Y., Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J. Gastroenterol. 9 (2003), 1307–1311.
149. [149] Li, J.H., Yu, J.P., Yu, H.G., Xu, X.M., Yu, L.L., Liu, J., Luo, H.S., Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediat. Inflamm. 2005 (2005), 185–193.
150. [150] Mei, Q., Xu, J.M., Xiang, L., Hu, Y.M., Hu, X.P., Xu, Z.W., Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad. Med. J. 81 (2005), 667–672.
151. [151] Marquez, E., Sánchez-Fidalgo, S., Calvo, J.R., la de Lastra, C.A., Motilva, V., Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J. Pineal Res. 40 (2006), 48–55.
152. [152] Mazzon, E., Esposito, E., Crisafulli, C., Riccardi, L., Muià, C., Di Bella, P., Meli, R., Cuzzocrea, S., Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J. Pineal Res. 41 (2006), 363–373.
153. [153] Nosál'ová, V., Zeman, M., Cerná, S., Navarová, J., Zakálová, M., Protective effect of melatonin in acetic acid induced colitis in rats. J. Pineal Res. 42 (2007), 364–370.
154. [154] Esposito, E., Mazzon, E., Riccardi, L., Caminiti, R., Meli, R., Cuzzocrea, S., Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J. Pineal Res. 45 (2008), 166–173.
155. [155] Akcan, A., Kucuk, C., Sozuer, E., Esel, D., Akyildiz, H., Akgun, H., Muhtaroglu, S., Aritas, Y., Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J. Gastroenterol. 14 (2008), 918–924.
156. [156] Tahan, G., Gramignoli, R., Marongiu, F., Aktolga, S., Cetinkaya, A., Tahan, V., Dorko, K., Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig. Dis. Sci. 56 (2011), 715–720.
157. [157] Sayyed, H.G., Jaumdally, R.J., Idriss, N.K., El Sers, D.A., Blann, A., The effect of melatonin on plasma markers of inflammation and on expression of nuclear factor-kappa beta in acetic acid-induced colitis in the rat. Dig. Dis. Sci. 58 (2013), 3156–3164.
158. [158] Trivedi, P.P., Jena, G.B., Melatonin reduces ulcerative colitis-associated local and systemic damage in mice: investigation on possible mechanisms. Dig. Dis. Sci. 58 (2013), 3460–3474.
159. [159] Esiringü, F., Tuğcu-Demiröz, F., Acartürk, F., Coşkun Cevher, Ş., Bircan, F., Sarı Kılıçaslan, S.M., Investigation of the effect of intracolonic melatonin gel formulation on acetic acid-induced colitis. Drug Deliv. Jul. 25 (2015), 1–9 (Epub ahead of print).
160. [160] Trivedi, P.P., Jena, G.B., Tikoo, K.B., Kumar, V., Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis. Mol. Carcinog. 55 (2016), 255–267.
161. [161] Tasdemir, S., Parlakpinar, H., Vardi, N., Kaya, E., Acet, A., Effect of endogen-exogenous melatonin and erythropoietin on dinitrobenzene sulfonic acid-induced colitis. Fundam. Clin. Pharmacol. 27 (2013), 299–307.
162. [162] Mann, S., Melatonin for ulcerative colitis?. Am. J. Gastroenterol. 98 (2003), 232–233.
163. [163] Maldonado, M.D., Calvo, J.R., Melatonin usage in ulcerative colitis: a case report. J. Pineal Res. 45 (2008), 339–340.
164. [164] Chang, C.L., Sung, P.H., Sun, C.K., Chen, C.H., Chiang, H.J., Huang, T.H., Chen, Y.L., Zhen, Y.Y., Chai, H.T., Chung, S.Y., Tong, M.S., Chang, H.W., Chen, H.H., Yip, H.K., Protective effect of melatonin-supported adipose-derived mesenchymal stem cells against small bowel ischemia-reperfusion injury in rat. J. Pineal Res. 59 (2015), 206–220.
165. [165] Lin, W.W., Karin, M., A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117 (2007), 1175–1183.
166. [166] Mudter, J., Neurath, M.F., Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 13 (2007), 1016–1023.
167. [167] Byun, M.S., Jeon, K.I., Choi, J.W., Shim, J.Y., Jue, D.M., Dual effect of oxidative stress on NF-kappakB activation in HeLa cells. Exp. Mol. Med. 34 (2002), 332–339.
168. [168] Macdonald, J., Galley, H.F., Webster, N.R., Oxidative stress and gene expression in sepsis. Br. J. Anaesth. 90 (2003), 221–232.
169. [169] Verma, I.M., Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann. Rheum. Dis. 2 (2004), 57–61.
170. [170] Norata, G.D., Marchesi, P., Pulakazhi Venu, V.K., Pasqualini, F., Anselmo, A., Moalli, F., Pizzitola, I., Garlanda, C., Mantovani, A., Catapano, A.L., Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120 (2009), 699–708.
171. [171] Savchenko, A.S., Inoue, A., Ohashi, R., Jiang, S., Hasegawa, G., Tanaka, T., Hamakubo, T., Kodama, T., Aoyagi, Y., Ushiki, T., Naito, M., Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol. Int. 61 (2011), 290–297.
172. [172] Ganguly, K., Kundu, P., Banerjee, A., Reiter, R.J., Swarnakar, S., Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin- induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radic. Biol. Med. 41 (2006), 911–925.
173. [173] Kim, H.J., Zheng, M., Kim, S.K., Cho, J.J., Shin, C.H., Joe, Y., Chung, H.T., CO/HO-1 induces NQO-1 expression via Nrf2 activation. Immune Netw. 11 (2011), 376–382.
174. [174] Ma, Q., Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 401–426.
175. [175] Khor, T.O., Huang, M.T., Kwon, K.H., Chan, J.Y., Reddy, B.S., Kong, A.N., Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res. 66 (2006), 11580–11584.
176. [176] Mott, J.D., Werb, Z., Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16 (2004), 558–564.
177. [177] di Mola, F.F., Di Sebastiano, P., Gardini, A., Innocenti, P., Zimmermann, A., Büchler, M.W., Friess, H., Differential expression of connective tissue growth factor in inflammatory bowel disease. Digestion 69 (2004), 245–253.
178. [178] Albarrán, M.T., López-Burillo, S., Pablos, M.I., Reiter, R.J., Agapito, M.T., Endogenous rhythms of melatonin, total antioxidant status and superoxide dismutase activity in several tissues of chick and their inhibition by light. J. Pineal Res. 30 (2001), 227–233.
179. [179] Brzozowski, T., Zwirska-Korczala, K., Konturek, P.C., Konturek, S.J., Sliwowski, Z., Pawlik, M., Kwiecien, S., Drozdowicz, D., Mazurkiewicz-Janik, M., Bielanski, W., Pawlik, W.W., Role of circadian rhythm and endogenous melatonin in pathogenesis of acute gastric bleeding erosions induced by stress. J. Physiol. Pharmacol. 58:Suppl. 6 (2007), 53–64.
180. [180] Esparza, J.L., Gómez, M., Rosa Nogués, M., Paternain, J.L., Mallol, J., Domingo, J.L., Melatonin reduces oxidative stress and increases gene expression in the cerebral cortex and cerebellum of aluminum-exposed rats. J. Pineal Res. 39 (2005), 129–136.
181. [181] Cabeza, J., Alarcón-de-la-Lastra, C., Martín, M.J., Herrerias, J.M., Motilva, V., Diurnal variation in the protective effect of melatonin against gastric injury caused by ischemia-reperfusion. Biol. Rhythm. Res. 33 (2002), 319–332.
182. [182] Lin, P.W., Stoll, B.J., Necrotising enterocolitis. Lancet 368 (2006), 1271–1283.
183. [183] Henry, M.C., Moss, R.L., Neonatal necrotizing enterocolitis. Semin. Pediatr. Surg. 17 (2008), 98–109.
184. [184] Neu, J., Walker, W.A., Necrotizing enterocolitis. N. Engl. J. Med. 364 (2011), 255–264.
185. [185] Hsueh, W., Caplan, M.S., Qu, X.W., Tan, X.D., De Plaen, I.G., Gonzalez-Crussi, F., Neonatal necrotizing enterocolitis: clinical considerations and pathogenetic concepts. Pediatr. Dev. Pathol. 6 (2003), 6–23.
186. [186] Caplan, M.S., Simon, D., Jilling, T., The role of PAF, TLR, and the inflammatory response in neonatal necrotizing enterocolitis. Semin. Pediatr. Surg. 14 (2005), 145–151.
187. [187] Zamora, R., Bryan, N.S., Boyle, P., Wong, C., Milsom, A.B., Jaffe, R., Feelisch, M., Ford, H.R., Nitrosative stress in an animal model of necrotizing enterocolitis. Free Radic. Biol. Med. 39 (2005), 1428–1437.
188. [188] Schnabl, K.L., Van Aerde, J.E., Thomson, A.B., Clandinin, M.T., Necrotizing enterocolitis: a multifactorial disease with no cure. World J. Gastroenterol. 14 (2008), 2142–2161.
189. [189] Perrone, S., Tataranno, M.L., Negro, S., Cornacchione, S., Longini, M., Proietti, F., Soubasi, V., Benders, M.J., Van Bel, F., Buonocore, G., May oxidative stress biomarkers in cord blood predict the occurrence of necrotizing enterocolitis in preterm infants?. J. Matern. Fetal Neonatal Med. 25:Suppl. 1 (2012), 128–131.
190. [190] Gitto, E., Marseglia, L., Manti, S., D'Angelo, G., Barberi, I., Salpietro, C., Reiter, R.J., Protective role of melatonin in neonatal diseases. Oxidative Med. Cell. Longev., 2013, 2013, 980374.
191. [191] Marseglia, L., D'Angelo, G., Manti, S., Aversa, S., Reiter, R.J., Antonuccio, P., Centorrino, A., Romeo, C., Impellizzeri, P., Gitto, E., Oxidative stress-mediated damage in newborns with necrotizing enterocolitis: a possible role of melatonin. Am. J. Perinatol. 32 (2015), 905–909.
192. [192] Sodhi, C.P., Neal, M.D., Siggers, R., Sho, S., Ma, C., Branca, M.F., Prindle, T. Jr., Russo, A.M., Afrazi, A., Good, M., Brower-Sinning, R., Firek, B., Morowitz, M.J., Ozolek, J.A., Gittes, G.K., Billiar, T.R., Hackam, D.J., Intestinal epithelial Toll-like receptor 4 regulates goblet cell development and is required for necrotizing enterocolitis in mice. Gastroenterology 143 (2012), 708–718.
193. [193] Saugstad, O.D., Mechanisms of tissue injury by oxygen radicals: implications for neonatal disease. Acta Paediatr. 85 (1996), 1–4.
194. [194] Trivedi, P.P., Jena, G.B., Tikoo, K.B., Kumar, V., Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis. Mol. Carcinog. 55 (2016), 255–267.
195. [195] Guven, A., Gundogdu, G., Uysal, B., Cermik, H., Kul, M., Demirbag, S., Ozturk, H., Oter, S., Hyperbaric oxygen therapy reduces the severity of necrotizing enterocolitis in a neonatal rat model. J. Pediatr. Surg. 44 (2009), 534–540.
196. [196] Guven, A., Gundogdu, G., Vurucu, S., Uysal, B., Oztas, E., Ozturk, H., Korkmaz, A., Medical ozone therapy reduces oxidative stress and intestinal damage in an experimental model of necrotizing enterocolitis in neonatal rats. J. Pediatr. Surg. 44 (2009), 1730–1735.
197. [197] Ozdemir, R., Yurttutan, S., Sarı, F.N., Uysal, B., Unverdi, H.G., Canpolat, F.E., Erdeve, O., Dilmen, U., Antioxidant effects of N-acetylcysteine in a neonatal rat model of necrotizing enterocolitis. J. Pediatr. Surg. 47 (2012), 1652–1657.
198. [198] Kul, M., Vurucu, S., Demirkaya, E., Tunc, T., Aydinoz, S., Meral, C., Kesik, V., Alpay, F., Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine. J. Pediatr. Gastroenterol. Nutr. 49 (2009), 85–89.
199. [199] Jaeschke, H., Preservation injury: mechanisms, prevention and consequences. J. Hepatol. 25 (1996), 774–780.
200. [200] Guven, A., Uysal, B., Gundogdu, G., Oztas, E., Ozturk, H., Korkmaz, A., Melatonin ameliorates necrotizing enterocolitis in a neonatal rat model. J. Pediatr. Surg. 46 (2011), 2101–2107.
201. [201] Cekmez, F., Cetinkaya, M., Tayman, C., Canpolat, F.E., Kafa, I.M., Uysal, S., Tunc, T., Sarıcı, S.Ü., Evaluation of melatonin and prostaglandin E1 combination on necrotizing enterocolitis model in neonatal rats. Regul. Pept. 184 (2013), 121–125.
202. [202] Davies, N.M., Longstreth, J., Jamali, F., Misoprostol therapeutics revisited. Pharmacotherapy 21 (2001), 60–73.
203. [203] Säfsten, B., Sjöblom, M., Flemström, G., Serotonin increases protective duodenal bicarbonate secretion via enteric ganglia and a 5-HT4-dependent pathway. Scand. J. Gastroenterol. 41 (2006), 1279–1289.